RAPT Therapeutics Faces Nasdaq Delisting Notice

RAPT Therapeutics ( (RAPT) ) has issued an update.

On May 21, 2025, RAPT Therapeutics received a notification from Nasdaq regarding its shares trading below the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. While this notice does not immediately impact the company’s stock listing, RAPT has until November 17, 2025, to regain compliance. The company plans to propose a reverse stock split to its shareholders to help maintain its Nasdaq listing. If compliance is not achieved, RAPT may seek additional time by transferring its listing to the Nasdaq Capital Market or face potential delisting.

The most recent analyst rating on (RAPT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.

Spark’s Take on RAPT Stock

According to Spark, TipRanks’ AI Analyst, RAPT is a Underperform.

RAPT Therapeutics’ overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.

To see Spark’s full report on RAPT stock, click here.

More about RAPT Therapeutics

RAPT Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of oral small molecule therapies for oncology and inflammatory diseases. The company is dedicated to advancing its pipeline of therapeutic candidates to address unmet medical needs.

Average Trading Volume: 949,667

Technical Sentiment Signal: Sell

Current Market Cap: $129.1M

Learn more about RAPT stock on TipRanks’ Stock Analysis page.